advertisement

Push Past in AD: Treatment Escalation in Moderate to Severe Atopic Dermatitis

Chapter 1: Chapter 1: Welcome and Introductions

6 chapters
60 minutes
Play All
CME/CE Broadcast Replay
ReachMD Healthcare Image
Media formats available:
Details
Program chapters
Presenters
  • Overview

    Join us for a replay of a dynamic live session where you'll gain valuable insights into assessing atopic dermatitis (AD) severity and applying guideline-aligned treatment strategies for patients with moderate to severe disease. Expert faculty will discuss practical approaches to treatment selection, therapeutic escalation, and the integration of newer AD therapies into clinical practice, while addressing common barriers to care and considerations for safe, evidence-based management. The session will also feature a patient perspective, providing firsthand insights into the lived experience of AD and the impact of treatment decisions on disease burden and quality of life.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.

    The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.

    Chair:
    Kristine Kucera, PA-C, MPAS, DHSc
    Physician Assistant
    Bare Dermatology
    Melissa, TX
    Adjunct Assistant Professor
    UNT Health Science Center
    Ft. Worth, TX
    Clinical Associate Professor
    UT Southwestern Medical Center
    Dallas, TX

    Consulting Fees: AbbVie, Alumis, Amgen, Galderma, Incyte, Johnson & Johnson, Leo, Lilly, Novartis, Sun, Takeda, UCB
    Employment:  Alumis, Inc. 

    Faculty: 
    Chava Bayla Wald
    Eczema Patient Advocate

    Research: Women’s College Hospital

    Reviewers/Planners/Authors: 

    • Rosanne Strauss, PharmD, MBA, has no relevant relationships to disclose. 
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
    • Cindy Davidson has no relevant relationships to disclose.  
  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Evaluate the full burden of atopic dermatitis (AD)
    • Identify patients with moderate to severe or uncontrolled AD who would benefit from treatment escalation
    • Optimize treatment selection in patients with moderate to severe or uncontrolled AD
    • Appraise comparative efficacy and safety of newer therapies for treatment of AD
    • Integrate guidelines and the latest clinical trial evidence into individualized treatment plans
  • Target Audience

    This activity has been designed to meet the educational needs of dermatologists, allergists, immunologists, and other advanced practice providers who treat patients with atopic dermatitis with uncontrolled itch and skin symptoms. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.00 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for a maximum of 1.00 contact hour(s)/ 0.1 CEUs of pharmacy continuing education credit.

    The Universal Activity Number (UAN) for this program is JA0006235-0000-26-139-H01-P. This learning activity is knowledge based. Upon successful completion of the activity, continuing education credit will be electronically submitted to the National Association of Boards of Pharmacy (NABP). Pharmacists with questions may contact NABP Customer Service at custserv@nabp.net. 

  • Provider(s)/Educational Partner(s)


    Global Learning Collaborative (GLC) designs and executes continuing education rooted in evidence-based medicine, clinical need, knowledge gap analysis, and careful consideration of learner feedback. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology is founded on a commitment to continuing medical education and the innovative assessment of its effects on clinical practice. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from AbbVie, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

    Reproduction Prohibited 
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Register

We're glad to see you're enjoying Prova Education…
but how about a more personalized experience?

Register for free